Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic
Plus Therapeutics, Inc. announced that its subsidiary, CNSide Diagnostics, has enrolled in Medicare, allowing it to submit claims for its CNSide® CSF Assay Platform. This milestone facilitates broader patient access and commercial adoption of its diagnostic tests for CNS cancers, particularly for identifying tumor cells in cerebrospinal fluid.
Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisions
Enables billing under traditional Medicare and creates a pathway to ~35 million Medicare Advantage beneficiaries through future payer coverage decisions